Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Acquired by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. boosted its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 23.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 67,068 shares of the company's stock after purchasing an additional 12,776 shares during the period. E Fund Management Co. Ltd. owned approximately 0.10% of Kymera Therapeutics worth $2,698,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of KYMR. Jennison Associates LLC grew its holdings in shares of Kymera Therapeutics by 85.8% during the third quarter. Jennison Associates LLC now owns 797,681 shares of the company's stock valued at $37,754,000 after buying an additional 368,394 shares during the last quarter. Wellington Management Group LLP grew its stake in Kymera Therapeutics by 7.2% during the 3rd quarter. Wellington Management Group LLP now owns 4,618,359 shares of the company's stock valued at $218,587,000 after purchasing an additional 308,954 shares during the last quarter. FMR LLC grew its stake in Kymera Therapeutics by 5.8% during the 3rd quarter. FMR LLC now owns 5,109,141 shares of the company's stock valued at $241,816,000 after purchasing an additional 282,301 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock valued at $6,649,000 after purchasing an additional 95,547 shares during the period. Finally, Cinctive Capital Management LP purchased a new position in shares of Kymera Therapeutics in the third quarter worth about $2,688,000.

Remove Ads

Insider Buying and Selling

In other Kymera Therapeutics news, insider Ellen Chiniara sold 2,241 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $42,112.35. Following the completion of the transaction, the chief operating officer now owns 67,800 shares in the company, valued at approximately $2,064,510. This trade represents a 2.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,788 shares of company stock worth $455,202 in the last 90 days. Insiders own 15.82% of the company's stock.

Kymera Therapeutics Stock Up 0.8 %

Shares of Kymera Therapeutics stock traded up $0.25 on Tuesday, reaching $33.27. The company's stock had a trading volume of 778,070 shares, compared to its average volume of 591,943. The company has a market capitalization of $2.16 billion, a P/E ratio of -14.22 and a beta of 2.22. The stock has a 50-day moving average price of $37.96 and a 200-day moving average price of $43.17. Kymera Therapeutics, Inc. has a 52-week low of $29.07 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The company had revenue of $7.39 million during the quarter, compared to analysts' expectations of $14.81 million. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. Sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

KYMR has been the topic of a number of recent research reports. BMO Capital Markets began coverage on Kymera Therapeutics in a research report on Friday, December 6th. They issued a "market perform" rating and a $55.00 target price on the stock. Leerink Partners reaffirmed an "outperform" rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Friday, December 27th. Stephens reissued an "overweight" rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Tuesday, January 21st. HC Wainwright boosted their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company raised Kymera Therapeutics from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. Three analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $56.69.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.